Biora Therapeutics reports positive results from its clinical trial of BT-600

seekingalpha04-04

Biora Therapeutics, Inc (NASDAQ:BIOR) shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2424957394?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-04 20:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2424957394","market":"fut","top_or_hot":-1,"title":"Biora Therapeutics reports positive results from its clinical trial of BT-600","media":"seekingalpha","content":"<div>\n<p>Biora Therapeutics, Inc (NASDAQ:BIOR) shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device ...</p>\n\n<a href=\"https://seekingalpha.com/news/4087220-biora-therapeutics-reports-positive-results-from-its-clinical-trial-of-bt-600\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biora Therapeutics reports positive results from its clinical trial of BT-600</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiora Therapeutics reports positive results from its clinical trial of BT-600\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-04 20:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4087220-biora-therapeutics-reports-positive-results-from-its-clinical-trial-of-bt-600><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biora Therapeutics, Inc (NASDAQ:BIOR) shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device ...</p>\n\n<a href=\"https://seekingalpha.com/news/4087220-biora-therapeutics-reports-positive-results-from-its-clinical-trial-of-bt-600\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BT","symbol_name":"英国电信","start_time":0,"source_url":"https://seekingalpha.com/news/4087220-biora-therapeutics-reports-positive-results-from-its-clinical-trial-of-bt-600","article_id":"2424957394","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2424957394","pubTimestamp":1712235321,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Biora Therapeutics, Inc  shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device that delivers a proprietary liquid formulation of tofacitinib to the colon. According to the interim clinical data, all pharmacokinetic endpoints were met in all study participants.  BT-600 was well tolerated with no serious adverse events. All devices performed as intended, with all participants receiving BT-600 showing systemic drug absorption. Source: Press Release    More on Biora Therapeutics  Biora Therapeutics, Inc.  Q4 2023 Earnings Call Transcript Biora Therapeutics announces $6M registered direct offering and concurrent private placement Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BT":"英国电信","BK4139":"生物科技","LENZ":"Therapeutics","BIOR":"Biora Therapeutics, Inc.","BK4196":"保健护理服务"},"translate_title":"Biora Therapeutics报告BT-600临床试验的阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIOR":1,"BT":1,"LENZ":1},"content_text":"Biora Therapeutics, Inc (NASDAQ:BIOR) shared additional positive interim results from clinical trial of BT-600, which is a drug-device combination consisting of the orally administered NaviCap device that delivers a proprietary liquid formulation of tofacitinib to the colon. According to the interim clinical data, all pharmacokinetic endpoints were met in all study participants.  BT-600 was well tolerated with no serious adverse events. All devices performed as intended, with all participants receiving BT-600 showing systemic drug absorption. Source: Press Release    More on Biora Therapeutics  Biora Therapeutics, Inc. (BIOR) Q4 2023 Earnings Call Transcript Biora Therapeutics announces $6M registered direct offering and concurrent private placement Biora Therapeutics announces new capital investment Seeking Alpha’s Quant Rating on Biora Therapeutics Historical earnings data for Biora Therapeutics","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2424957394"}